Amneal FDA Monday, June 27, 2016 +0.20 Positive

FDA Approves DOXYCYCLINE HYCLATE — Amneal Pharmaceuticals NY LLC

Amneal Pharmaceuticals NY LLC secured final FDA approval on June 27, 2016, for its Abbreviated New Drug Application (ANDA207289) of the broad-spectrum antibiotic Doxycycline Hyclate. Regaining market exclusivity for this essential generic drug positions the company to capitalize on steady prescription volume amidst continued competition.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed